AbbVie Inc (ABBV)vsAzenta Inc (AZTA)
ABBV
AbbVie Inc
$291.31
+1.07%
HEALTHCARE · Cap: $521.11B
AZTA
Azenta Inc
$39.16
+4.76%
HEALTHCARE · Cap: $1.81B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 10655% more annual revenue ($66.01B vs $613.81M). ABBV leads profitability with a 15.7% profit margin vs -20.0%. AZTA appears more attractively valued with a PEG of 0.53. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
AZTA
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.31
$134.02 premium
Margin of Safety
+34.6%
Fair Value
$46.55
Current Price
$39.16
$7.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. Revenue growth of 12.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : AZTA
The primary concerns for AZTA are Market Cap, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
ABBV profiles as a mature stock while AZTA is a turnaround play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.52 — expect wider price swings.
AZTA is growing revenue faster at 12.0% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 55/100), backed by strong 15.7% margins and 10.3% revenue growth. AZTA offers better value entry with a 34.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?